Profound Medical (PROF) announce that its TULSA-PRO system installed base stood at 78 as of December 31, 2025 – higher than its previously announced goal of 75 installs by the end of 2025. Profound’s TULSA-PRO qualified sales pipeline also grew to 97 new systems being classified within one of the “Verify, Negotiate and Contracting” stages at year-end. “As the installed base grows, we expect that it will lead to higher patient treatment rates and, correspondingly, continued growth of our high margin recurring revenue,” said Profound’s CEO and Chairman, Arun Menawat. “That is being driven primarily by the TULSA Procedure’s ability to treat an unrivaled range of prostate diseases, severities, and aggressions, while preserving crucial functions like continence and sexual health of the patient. We look forward to releasing our fourth quarter and full year 2025 financial results near the end of February 2026.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical price target raised to $12 from $11 at Lake Street
- Profound Medical’s TULSA-PRO Marks First Commercial Case at Johns Hopkins
- Profound Medical says Johns Hopkins treats first commercial TULSA-PRO case
- Profound Medical Raises US$6.45 Million in Canadian Private Placement
- Profound Medical Upsizes Private Placement to Raise US$6.45 Million